Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CYTO Altamira Therapeutics	$0.30 -25.9%	$0.36	$0.30 ▼ $2.47	$1.02M	1.8	567,070 shs	753,013 shs
OGEN Oragenics	$0.19 -3.2%	$0.23	$0.16 ▼ $3.43	$3.99M	0.87	1.67 million shs	112,040 shs
SONN Sonnet BioTherapeutics	$1.43 +1.9%	$1.36	$1.10 ▼ $16.00	$4.38M	0.58	380,981 shs	124,482 shs
SXTP 60 Degrees Pharmaceuticals	$2.68 +5.1%	$2.25	$1.41 ▼ $35.99	$3.95M	3.41	549,194 shs	96,130 shs

20 High-Yield Dividend Stocks that Could Ruin Your Retirement

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CYTO Altamira Therapeutics	0.00%	0.00%	0.00%	0.00%	-80.89%
OGEN Oragenics	+0.21%	+2.67%	-11.15%	-35.79%	-80.99%
SONN Sonnet BioTherapeutics	-5.77%	+9.26%	+7.18%	-16.92%	-21.12%
SXTP 60 Degrees Pharmaceuticals	-8.60%	-4.49%	+37.10%	-51.89%	+114.29%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CYTO Altamira Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
OGEN Oragenics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SONN Sonnet BioTherapeutics	1.3951 of 5 stars	3.5	2.0	0.0	0.0	1.9	0.0	0.0
SXTP 60 Degrees Pharmaceuticals	0.4734 of 5 stars	0.0	2.0	0.0	0.0	2.3	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CYTO Altamira Therapeutics	0.00	N/A	N/A	N/A
OGEN Oragenics	0.00	N/A	N/A	N/A
SONN Sonnet BioTherapeutics	3.00	Buy	$20.00	1,298.60% Upside
SXTP 60 Degrees Pharmaceuticals	2.00	Hold	N/A	N/A

Current Analyst Ratings Breakdown

Latest CYTO, OGEN, SONN, and SXTP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/24/2025	SXTP 60 Degrees Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
4/8/2025	SXTP 60 Degrees Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
4/7/2025	SONN Sonnet BioTherapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
3/28/2025	SONN Sonnet BioTherapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
3/28/2025	SXTP 60 Degrees Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
3/22/2025	SXTP 60 Degrees Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
3/7/2025	SXTP 60 Degrees Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
2/25/2025	SXTP 60 Degrees Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
2/19/2025	SXTP 60 Degrees Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
2/1/2025	SXTP 60 Degrees Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)

(Data available from 4/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CYTO Altamira Therapeutics	$320K	3.19	N/A	N/A	$4.56 per share	0.07
OGEN Oragenics	$40K	99.75	N/A	N/A	$0.61 per share	0.30
SONN Sonnet BioTherapeutics	$1M	4.38	N/A	N/A	$1.32 per share	1.08
SXTP 60 Degrees Pharmaceuticals	$607.57K	6.50	N/A	N/A	($10.45) per share	-0.26

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CYTO Altamira Therapeutics	-$4.31M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
OGEN Oragenics	-$20.66M	-$1.70	N/A	∞	N/A	N/A	-2,087.95%	-486.56%	N/A
SONN Sonnet BioTherapeutics	-$7.44M	N/A	0.00	∞	N/A	N/A	-408.93%	-174.13%	5/13/2025 (Estimated)
SXTP 60 Degrees Pharmaceuticals	-$3.77M	-$50.41	N/A	N/A	N/A	N/A	N/A	-113.43%	5/21/2025 (Estimated)

Latest CYTO, OGEN, SONN, and SXTP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/21/2025	Q1 2025	SXTP 60 Degrees Pharmaceuticals	-$1.31	N/A	N/A	N/A	N/A	N/A
5/13/2025	Q2 2025	SONN Sonnet BioTherapeutics	-$0.92	N/A	N/A	N/A	N/A	N/A
2/13/2025	Q1 2025	SONN Sonnet BioTherapeutics	-$11.12	-$1.56	+$9.56	-$1.56	N/A	$1,000.00 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CYTO Altamira Therapeutics	N/A	N/A	N/A	N/A	N/A
OGEN Oragenics	N/A	N/A	N/A	N/A	N/A
SONN Sonnet BioTherapeutics	N/A	N/A	N/A	N/A	N/A
SXTP 60 Degrees Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CYTO Altamira Therapeutics	N/A	0.43	N/A
OGEN Oragenics	N/A	1.93	1.93
SONN Sonnet BioTherapeutics	N/A	2.15	2.15
SXTP 60 Degrees Pharmaceuticals	N/A	5.26	4.92

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CYTO Altamira Therapeutics	1.91%
OGEN Oragenics	18.71%
SONN Sonnet BioTherapeutics	9.45%
SXTP 60 Degrees Pharmaceuticals	7.96%

Insider Ownership

Company	Insider Ownership
CYTO Altamira Therapeutics	13.03%
OGEN Oragenics	10.10%
SONN Sonnet BioTherapeutics	2.00%
SXTP 60 Degrees Pharmaceuticals	10.27%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CYTO Altamira Therapeutics	20	3.40 million	2.96 million	Not Optionable
OGEN Oragenics	5	21.48 million	10.98 million	N/A
SONN Sonnet BioTherapeutics	10	3.07 million	3.01 million	Not Optionable
SXTP 60 Degrees Pharmaceuticals	3	1.47 million	6.61 million	Not Optionable

CYTO, OGEN, SONN, and SXTP Headlines

Recent News About These Companies

60 Degrees Pharmaceuticals (NASDAQ:SXTP) Earns "Sell (E+)" Rating from Weiss Ratings

April 26, 2025 | americanbankingnews.com

Babesiosis Disease Burden in United States is Substantially Higher Than Official Estimates, According to Preliminary Results of 60 Degrees Pharma Survey

April 22, 2025 | globenewswire.com

Why 60 Degrees Pharmaceuticals, Inc. (SXTP) Went Down On Thursday?

April 10, 2025 | insidermonkey.com

Geoff Dow, PhD, Infectious Disease Product Development Expert, to Discuss Babesiosis at Healing Lyme Summit, April 15-21

April 10, 2025 | globenewswire.com

Geoff Dow, PhD, Infectious Disease Product Development Expert, to Discuss Babesiosis at Healing Lyme Summit, April 15-21

April 10, 2025 | globenewswire.com

Sixty Degrees Pharmaceuticals Announces Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention with Yale School of Medicine and Yale School of Public Health

April 8, 2025 | globenewswire.com

60 Degrees Pharmaceuticals, Inc.

April 4, 2025 | uk.investing.com

60 Degrees Pharmaceuticals and Fathom Holdings Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

February 21, 2025 | accessnewswire.com

60 Degrees Pharmaceuticals announces 1-for-5 reverse stock split

February 20, 2025 | markets.businessinsider.com

60 Degrees Pharmaceuticals, Inc. Announces 1-for-5 Reverse Stock Split to Comply with Nasdaq Listing Requirements

February 20, 2025 | quiverquant.com

60 Degrees Pharmaceuticals, Inc. Announces 1:5 Reverse Stock Split

February 20, 2025 | globenewswire.com

60 Degrees says FDA does not object to tafenoquine import plan

February 11, 2025 | markets.businessinsider.com

60 Degrees Pharmaceuticals, Inc. Receives FDA Approval for Importing KODATEF® as Preemptive Measure for ARAKODA® Supply Stability

February 11, 2025 | quiverquant.com

Sixty Degrees Pharmaceuticals to Ensure Continuity of Tafenoquine Supply in U.S. by Importing Limited Quantity of KODATEF®

February 11, 2025 | globenewswire.com

Insiders Give Up US$71k As 60 Degrees Pharmaceuticals Stock Drops To US$0.55

February 9, 2025 | finance.yahoo.com

60 Degrees Pharmaceuticals, Inc. Closes Registered Direct Offering and Concurrent Private Placement Raising Approximately $1.075 Million

February 6, 2025 | quiverquant.com

60 Degrees Pharma Announces Closing of $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

February 6, 2025 | globenewswire.com

60 Degrees prices 1.5M shares at 71.5c in registered direct offering

February 5, 2025 | markets.businessinsider.com

60 Degrees Pharmaceuticals, Inc. Announces $1.075 Million Registered Direct Offering and Concurrent Private Placement of Common Stock and Warrants

February 5, 2025 | quiverquant.com

60 Degrees Pharma Announces $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

February 5, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Are Tariffs Threatening Disney’s Comeback Story?
By Jea Yu | April 9, 2025
View Are Tariffs Threatening Disney’s Comeback Story?
Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?
By Jeffrey Neal Johnson | April 25, 2025
View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?
Signs of a more buyer-friendly housing market emerge for the spring homebuying season
By The Associated Press | April 6, 2025
View Signs of a more buyer-friendly housing market emerge for the spring homebuying season
5 Highest-Rated Dividend Stocks According to MarketBeat
By Thomas Hughes | April 10, 2025
View 5 Highest-Rated Dividend Stocks According to MarketBeat
Cellectis Charts Course for 2025 With Boost From AstraZeneca Deal
By Jeffrey Neal Johnson | April 22, 2025
View Cellectis Charts Course for 2025 With Boost From AstraZeneca Deal

CYTO, OGEN, SONN, and SXTP Company Descriptions

Altamira Therapeutics NASDAQ:CYTO

Altamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland and Australia. The company develops and supplies OligoPhore/SemaPhore platforms, which are peptide-based nanoparticle technologies for ribonucleic acid delivery to extrahepatic tissues. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is developing AM-401 for the treatment of KRAS driven cancer; AM-411 for the treatment of rheumatoid arthritis; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase II/III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It also offers Bentrio, a drug-free nasal spray for protection against airborne viruses and allergens. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. The company was founded in 2003 and is based in Hamilton, Bermuda.

Oragenics NYSE:OGEN

$0.19 -0.01 (-3.23%)

As of 04:00 PM Eastern

Oragenics, Inc., a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.

Sonnet BioTherapeutics NASDAQ:SONN

$1.43 +0.03 (+1.85%)

As of 04:00 PM Eastern

Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 that is in Phase 1b/2a clinical trial for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6, which is in Phase 1b/I2a clinical trail to treat chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy; and SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer. It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6; and strategic development collaboration with Sarcoma Oncology Center to advance SON-1210. The company is headquartered in Princeton, New Jersey.

60 Degrees Pharmaceuticals NASDAQ:SXTP

$2.68 +0.13 (+5.10%)

As of 04:00 PM Eastern

60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is headquartered in Washington, the District of Columbia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time